Cardiomyopathy: mavacamten shows sharp outflow-gradient reduction in real-world China data

Real-world evidence from a 30-week study in China reports that mavacamten sharply reduced resting outflow tract gradients versus conventional therapy, with biomarker improvements but close attention required for ejection fraction decline. The dataset followed 222 patients and reported resting gradients of 23.76 mmHg on mavacamten compared with 78.49 mmHg on conventional therapy. The findings reinforce the ongoing repositioning of myosin inhibitors in obstructive hypertrophic cardiomyopathy from trial outcomes toward monitoring-led clinical practice, where cardiomyac and lab follow-up cadence can determine safe use. For clinicians and biotech operators, the results provide additional parameters for pragmatic dosing and surveillance expectations in broader patient populations outside controlled trials.